Overview / Abstract: |
STATEMENT OF NEED Colorectal cancer (CRC) is the third leading cause of cancer death among men and women in the United States. An estimated 145,600 new cases are diagnosed annually and 51,020 people die of the disease. When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because CRC initially exhibits no symptoms and the use of routine screening is suboptimal, most patients are diagnosed at later stages. Approximately 21% of patients present with metastatic disease, which is associated with a 5-year survival rate of only 14%. TARGET AUDIENCE Medical oncologists, gastroenterologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with CRC. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: 1.) Distinguish prognostic factors that can help tailor treatment to individual patients with metastatic CRC FACULTY Tanios S. Bekaii-Saab, MD (Chairperson) |
Expiration |
Oct 12, 2021 |
Discipline(s) |
Nurse Practitioner , Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
1.0 CME, MOC |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Tanios S. Bekaii-Saab, MD |
Activity Specialities / Related Topics |
Adverse Drug Reactions / ADR, Gastroenterology / GI, Oncology / Cancer / Radiation Therapy |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Amgen. |
Keywords / Search Terms |
i3 Health i3 Health, CME, free CME, colorectal cancer, CRC, oncology, ILNA points, free CE, free CE CME Free CE CME |